Anagram Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Anagram Therapeutics?

Anagram Therapeutics has 3 investors including Blackstone Life Sciences And Miller Family Trust.

Q: How much funding has Anagram Therapeutics raised to date?

Anagram Therapeutics has raised obfuscated.

Overview

Anagram Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

+2 more milestones

See more interactive data and historical milestones on desktop for the best experience

About Anagram Therapeutics

CB Rank

1044

Anagram Therapeutics develops orally delivered enzyme therapies for malabsorption syndromes and nutrient deficiencies.

Founded

obfuscation

Private

Private Equity

Boston, Massachusetts, United States

11-50

anagramtx.com

Biotechnology

Information Technology

Medical

Therapeutics

Funding Rounds

Private Equity

OBF

obfuscation

Venture - Series Unknown

OBF

obfuscation

Grant

OBF

obfuscation

Key People

Shenda Baker: Chief Science Officer & Board Member
Past Role: Synedgen, President & COO
William P. Wiesmann: Chairman

Details

Legal Name

Anagram Therapeutics, Inc.

Also Known As

Synspira, Synspira, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Robert Gallotto, Shenda Baker

About the Company

Anagram Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, orally delivered enzyme therapeutics. These therapies aim to treat serious diseases caused by malabsorption syndromes and nutrient deficiencies. The company is dedicated to advancing enzyme replacement therapies that are currently entering

clinicaltrials, particularly for conditions such as cystic fibrosis. Anagram Therapeutics leverages its expertise in biotechnology to create innovative solutions for unmet medical needs.

Phone Number

+1 617 466 3111

Contact Email

info@synspira.com

Diversity Spotlight

Women Founded

Women Led

Predictions & Insights

Growth Insight

See this Growth Insight

Anagram Therapeutics is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Runway Speculation

Products & Services

ANG003

An orally delivered enzyme replacement therapy for exocrine pancreatic insufficiency and malabsorption syndromes, combining lipase, protease, and amylase enzymes.

ANG011

An orally delivered enzyme therapy engineered to break down specific carbohydrates in congenital malabsorptive syndrome caused by enzyme deficiencies.

Research & Development

Anagram Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity
obfuscated obfuscation	Private Equity Round - Anagram Therapeutics	1	obfuscated obfuscation	Blackstone Life Sciences	Private Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Blackstone Life Sciences	Yes	Private Equity Round - Anagram Therapeutics	Kiran Reddy, Nicholas Galakatos
Blackstone Life Sciences	Yes	Private Equity Round - Anagram Therapeutics	Kiran Reddy, Nicholas Galakatos
Blackstone Life Sciences	Yes	Private Equity Round - Anagram Therapeutics	Kiran Reddy, Nicholas Galakatos
Blackstone Life Sciences	Yes	Private Equity Round - Anagram Therapeutics	Kiran Reddy, Nicholas Galakatos
Blackstone Life Sciences	Yes	Private Equity Round - Anagram Therapeutics	Kiran Reddy, Nicholas Galakatos